2.6. Advances in CD123-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for BPDCN and Hematologic Malignancies. The gene discussed is IL3RA; the disease is CD4+/CD56+ hematodermic neoplasm.